• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
New FDA Clearance Validates In Vivo, Real-Time Identification of Cellular and Vascular Organization and Architecture Using Cellvizio®

New FDA Clearance Validates In Vivo, Real-Time Identification of Cellular and Vascular Organization and Architecture Using Cellvizio®

by Zina | Dec 18, 2017 | News

Pivotal regulatory milestone positioning Cellvizio as unique real-time in vivo visualization system Cellvizio platform complementary to a wide range of interventional imaging and surgical robotics systems Mauna Kea Technologies announced today that it has...
Mauna Kea Technologies Renews its Equity Financing Facility to Support its Development

Mauna Kea Technologies Renews its Equity Financing Facility to Support its Development

by Zina | Dec 4, 2017 | News

Please download the official press release for full details
Mauna Kea Technologies Announces Reimbursement Coverage For Cellvizio® In Croatia

Mauna Kea Technologies Announces Reimbursement Coverage For Cellvizio® In Croatia

by Zina | Nov 16, 2017 | News

Croatian Health Insurance Fund Now Provides Reimbursement for Cellvizio® advanced endomicroscopy technology for patients affected by gastrointestinal, biliopancreatic, respiratory, and urinary diseases Mauna Kea Technologies announced today that the Croatian...
New Contact Study Analysis Demonstrates Cellvizio’s Ability to Improve The Management of Patients with Pancreatic Cysts

New Contact Study Analysis Demonstrates Cellvizio’s Ability to Improve The Management of Patients with Pancreatic Cysts

by Zina | Oct 30, 2017 | News

New CONTACT Study Outcomes Presented today in Late-Breaking Session at United European Gastroenterology Week (UEGW) 2017 Mauna Kea Technologies today announced that Cellvizio was featured in several presentations at the United European Gastroenterology Week (UEGW)...
Mauna Kea Technologies Renews its Equity Financing Facility to Support its Development

Appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer

by Zina | Oct 17, 2017 | News

Mauna Kea Technologies announced the appointment of Olivier Regnard to the position of Deputy Chief Executive Officer and Chief Financial Officer, effective immediately. Mr. Regnard brings nearly 20 years of finance, accounting and operational experience to the...
« Older Entries
Next Entries »

Articles récents

  • ‘Never a Dull Moment’ Dr. Ravi Prakash Keeps Patients Front and Center
  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}